IDRA · Idera Pharmaceuticals Inc

-

Please sign in to comment on IDRA

1 Comment

Admin

4 years, 1 month ago

Idera Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 61.7% below its 200 day moving average.

From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.1.

Idera Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 230.2% to $-77M since the same quarter in the previous year.

Finally, its free cash flow grew by 26.7% to $-8M since the same quarter in the previous year.

Based on the above factors, Idera Pharmaceuticals, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US45168K4058
Industry	Biotechnology
Sector	Healthcare

Market Cap	27M
PE Ratio	None
Beta	1.3
Target Price	1
Dividend Yield	0.0%

ABOUT

Idera Pharmaceuticals Inc

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

IDRA · Idera Pharmaceuticals Inc

-

Idera Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Idera Pharmaceuticals Inc using a moving average strategy